Naitoh N, Washizuka T, Takahashi K, Miyajima T, Aizawa Y
First Department of Internal Medicine, Niigata University School of Medicine, Japan.
Jpn Heart J. 1998 May;39(3):307-19. doi: 10.1536/ihj.39.307.
Electrophysiologic testing was performed in 31 patients with ventricular tachycardia (21 cases) and fibrillation (10 cases) to characterize the electrophysiologic properties of patients responding or not responding to therapy with class III antiarrhythmic drugs. At the baseline, there were no differences among the patients in the monomorphic VT cycle length (CL), block CL or the width of the zone of entrainment. Ventricular tachyarrhythmias after the administration of class III drugs (sotalol: 9, amiodarone: 15 and E-4031/MS-551: 7) were inducible (non-responders) in 17 patients and non-inducible (responders) in 14 (45%). The class III drugs prolonged the sinus cycle length (SCL), QT interval and right ventricular effective refractory period (VERP), but had little effect on ventricular conduction time in the responders and non-responders. The SCL, QT interval and VERP at the three drive cycle lengths of 600, 400 and 300 msec were significantly longer in the responders than in the non-responders, but the class III drug action on VERP showed a reverse use-dependency. Isoproterenol administered to the responder did not fully reverse the class III antiarrhythmic drug-induced prolongation of QT, QTc and VERP, which remained significantly prolonged compared to the baseline values. Furthermore, when the VERP after the administration of class III drugs were greater than 270, 250 and 240 msec at the three drive cycle lengths of 600, 400 and 300 msec, respectively, it was associated with the non-inducibility of VT/VF. Though the precise mechanism of the drug efficacy is not yet known, these observations help to clarify the ability of class III drugs to prevent the induction of ventricular tachyarrhythmia.
对31例室性心动过速(21例)和颤动(10例)患者进行了电生理检查,以明确对Ⅲ类抗心律失常药物治疗有反应或无反应患者的电生理特性。基线时,单形性室性心动过速周期长度(CL)、阻滞CL或拖带区宽度在患者之间无差异。给予Ⅲ类药物(索他洛尔9例、胺碘酮15例和E-4031/MS-551 7例)后,17例患者的室性快速心律失常可诱发(无反应者),14例(45%)不可诱发(有反应者)。Ⅲ类药物延长了窦性周期长度(SCL)、QT间期和右心室有效不应期(VERP),但对有反应者和无反应者的心室传导时间影响不大。在600、400和300毫秒这三个驱动周期长度时,有反应者的SCL、QT间期和VERP显著长于无反应者,但Ⅲ类药物对VERP的作用表现出反向频率依赖性。给予有反应者异丙肾上腺素并不能完全逆转Ⅲ类抗心律失常药物引起的QT、QTc和VERP延长,与基线值相比仍显著延长。此外,当在600、400和300毫秒这三个驱动周期长度时,给予Ⅲ类药物后的VERP分别大于270、250和240毫秒时,与室性心动过速/心室颤动不可诱发相关。虽然药物疗效的确切机制尚不清楚,但这些观察结果有助于阐明Ⅲ类药物预防室性快速心律失常诱发的能力。